Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers and ECP in Acute GVHD
NCT02322190Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2014
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of methoxsalen in Acute Graft-Versus-Host Disease (aGvHD), sponsored by National Cancer Institute. Started Dec 2014; status: terminated.
02
Drugs
methoxsalen
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02322190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02322190.